Single‐cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: What are the best predictors of remission and prognosis?

There is controversy over the concept of function and organ preservation by chemotherapy/chemoradiation instead of surgery in locally advanced cancer of the larynx or pharynx. Tumor response to induction chemotherapy (ICT) can help in choosing between conservative and surgical treatment. This study compared 3 methods of assessing response to ICT: endoscopy, computed tomography, and 18F‐FDG‐PET/CT.

[1]  T. Stöver,et al.  Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck , 2014, Strahlentherapie und Onkologie.

[2]  B. Maciejewski,et al.  Prognostic role of tumor volume for radiotherapy outcome in patient with T2 laryngeal cancer , 2013, Strahlentherapie und Onkologie.

[3]  F. Hoebers,et al.  Definitive radiation therapy for treatment of laryngeal carcinoma , 2013, Strahlentherapie und Onkologie.

[4]  D. Aebersold,et al.  Taxane-containing induction chemotherapy followed by definitive chemoradiotherapy , 2013, Strahlentherapie und Onkologie.

[5]  H. Harada,et al.  Early evaluation of neoadjuvant chemotherapy response using FDG-PET/CT predicts survival prognosis in patients with head and neck squamous cell carcinoma , 2013, International Journal of Clinical Oncology.

[6]  H. Iro,et al.  Results of chemoselection with short induction chemotherapy followed by chemoradiation or surgery in the treatment of functionally inoperable carcinomas of the pharynx and larynx. , 2013, Oral oncology.

[7]  R. Weber,et al.  Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. Khuri,et al.  Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[9]  G. Calais,et al.  Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Vokes,et al.  DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). , 2012 .

[11]  M. Kikuchi,et al.  Sequential FDG-PET/CT after Neoadjuvant Chemotherapy is a Predictor of Histopathologic Response in Patients with Head and Neck Squamous Cell Carcinoma , 2011, Molecular Imaging and Biology.

[12]  G. Calais,et al.  Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. , 2009, Journal of the National Cancer Institute.

[13]  K. Frey,et al.  Advanced squamous cell carcinoma of the oropharynx: Efficacy of positron emission tomography and computed tomography for determining primary tumor response during induction chemotherapy , 2009, Head & neck.

[14]  C. Tsien,et al.  Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Wolfgang A Weber,et al.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. , 2007, The Lancet. Oncology.

[16]  Kirk P. Withrow,et al.  Free Tissue Transfer to Manage Salvage Laryngectomy Defects After Organ Preservation Failure , 2007, The Laryngoscope.

[17]  M. Schwaiger,et al.  Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Eisbruch,et al.  Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Otto S Hoekstra,et al.  Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Wust,et al.  Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. D. Van den Abbeele,et al.  Positron emission tomography with 18F‐fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer , 2004, Head & neck.

[22]  R. Weber,et al.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. , 2003, The New England journal of medicine.

[23]  L. Collette,et al.  Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. , 1996, Journal of the National Cancer Institute.

[24]  W. Hong,et al.  Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. , 1991, The New England journal of medicine.

[25]  F. Cognetti,et al.  Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  F. Cognetti,et al.  Neoadjuvant chemotherapy in previously untreated patients with advanced head and neck squamous cell cancer , 1988, Cancer.

[27]  J. Jacobs,et al.  Correlation between response to cisplatinum‐combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck , 1984, Cancer.

[28]  C. García-Girón,et al.  A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  M. Uder,et al.  Feasibility, Toxicity, and Efficacy of Short Induction Chemotherapy of Docetaxel Plus Cisplatin or Carboplatin (TP) Followed by Concurrent Chemoradio ­ therapy for Organ Preservation in Advanced Cancer of the Hypopharynx, Larynx, and Base of Tongue , 2010, Strahlentherapie und Onkologie.

[30]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[31]  R. Weber,et al.  Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. , 2003, Archives of otolaryngology--head & neck surgery.